10X GENOMICS INC CLASS A (TXG)
Health Care · Single-cell and spatial genomics / life sciences instrumentation · NASDAQ
10x Genomics provides microfluidic and spatial transcriptomics instruments and consumables that enable researchers to analyze individual cells and tissue architecture at previously inaccessible resolution and scale.
What 10X GENOMICS INC CLASS A does
10x Genomics is a life sciences technology company that builds integrated research solutions—instruments, consumables, and software—to interrogate, understand, and master biology at single-cell and high-spatial resolution. The company's platforms enable researchers to analyze millions of individual cells or tissue sample positions, generating foundational insights across oncology, immunology, neuroscience, and other biological disciplines. Since 2015, 10x has sold over 8,000 instruments globally to academic, translational, and biopharmaceutical researchers and supports a body of 10,000+ peer-reviewed publications.
Themes: ["single-cell genomics","spatial transcriptomics","single-cell RNA sequencing","multiomics","research biology tools","precision biology"]
Fundamentals
- Price$43.10 as of 2026-07-09 close
- Market cap$5.4B as of 2026-07-10
- 1-year return+256.2% as of 2026-07-09 close
- Net margin-3.5% as of 2026-07-10
- Gross margin+69.7% as of 2026-07-10
- ROE-2.9% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+2.3% as of 2026-07-10
- Revenue CAGR (3y)+7.6% SEC XBRL
- Beta2.07 as of 2026-07-10
Key risks (from latest filing)
["Reliance on consumables revenue and adoption rates; declining consumable reactions (357,100 in 2024 to 424,000 in 2025 but modest revenue growth of 5% YoY with negative net margins) suggests pricing or market demand pressures.","Regulatory and clinical pathway execution; the company expects to enter clinical and diagnostic markets, a highly regulated transition with uncertain timing and approval outcomes.","Competition and market saturation in single-cell and spatial genomics from academic, commercial, and potential new entrants with different technologies."]
Competitors & peers
- Illumina
- Parse Biosciences
- Berkeley Lights
- BD Biosciences
- Nanostring Technologies
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.